Atif Abbas has over 25 years of pharmaceutical and biotechnology leadership with extensive experience guiding drug development programmes from preclinical stages through clinical trials to market approval and will drive clinical excellence through to commercialisation.

He has successfully led numerous first-in-human IND submissions for immunotherapy compounds, including PDL1-41bb bispecific antibodies, NKG2A antibodies, and STING agonists, while playing pivotal roles in high-profile regulatory submissions such as the successful BLA filing for Avelumab in Merkel cell carcinoma.

Alongside his role as Chief Medical Officer at Trogenix, he also serves as Chief Medical Officer at Storm Therapeutics [in a fractional capacity]. Prior to this, Atif served as VP and Head of Immuno-oncology at Servier Pharma. Previously, he built and led multidisciplinary clinical development teams across senior roles at Spring Bank Pharma, Kadmon (acquired by Sanofi for $1.9B in 2021), Merck and AbbVie.

Atif earned his medical degree from King Edward Medical University in Lahore, Pakistan, completed oncology training at Mayo Hospital, and pursued clinical research at Yale-Griffin Hospital in the U.S. He is a graduate of the Global Clinical Scholars Research Programme at Harvard Medical School and a widely published author in oncology and medical safety.